Immune Design (NASDAQ: IMDZ) reported Q3 EPS of ($0.60), $0.11 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $1.73 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.